medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2014-10-6-11medsovet-650Research ArticleЛЕЧЕНИЕ ИПРОФИЛАКТИКА ИНСУЛЬТАTREATMENT AND PREVENTION OF STROKEВедение больного, перенесшего ишемический инсульт. Применение цитиколинаManagement of patients after ischemic stroke. Use of citicolineПарфеновВ. А.ParfyonovV. A.noemail@neicon.ruПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияFirst Moscow State Medical University named after I.M. SechenovRussian Federation201430122014010611Copyright © Парфенов В.А., 20142014Парфенов В.А.Parfyonov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/650

Пациенту, перенесшему ишемический инсульт (ИИ), необходима постоянная профилактика повторного ИИ, которая основывается на модификации образа жизни, использовании лекарственных средств (антигипертензивных, антитромботических и статинов) и у части пациентов хирургических методов лечения (каротидная эндартерэктомия или стентирование). В зависимости от имеющихся неврологических нарушений показаны различные реабилитационные программы, которые в большинстве случаев требуют физической и умственной активизации пациента и могут сочетаться с различными лекарственными средствами (для терапии спастичности, депрессии, когнитивных нарушений). Представлены данные многоцентровых плацебо-контролируемых исследований по изучению эффективности и безопасности цитиколина (Цераксона) при ИИ. Отмечается, что цитиколин имеет несомненное преимущество перед другими лекарственными средствами, широко применяемыми в нашей стране в остром и восстановительном периодах ИИ.

In ischemic stroke (IS) patients, preventive actions against recurrent IS are required on a permanent basis, including lifestyle changes, medication therapy (antihypertensive, antiplatelet and statin drugs) and, in some patients, surgical treatment (carotid endarterectomy, or stenting). Depending on the type of the neurological disorder, various rehabilitation programs are indicated which in most cases require physical and mental activation of the patient and can be combined with various medicines (treatment of spasticity, depression, cognitive impairment). Results of multicenter, placebo-controlled studies on the efficacy and safety of citicoline (Ceraxon) for IS are presented. Citicoline is said to have a definite advantage over other drugs commonly used in this country for acute IS and in the recovery period.

вторичная профилактика ишемического инсультареабилитация при ишемическом инсультецитиколинsecondary prevention of ischemic strokeischemic stroke rehabilitationciticolineReferencesДамулин И.В., Парфенов В.А., Скоромец А.А., Яхно Н.Н. Нарушения кровообращения в головном и спинном мозге. Болезни нервной системы. Руководство для врачей. Под ред. Н.Н. Яхно. М.: Медицина, 2005, 1: 232-303.Дамулин И.В., Парфенов В.А., Скоромец А.А., Яхно Н.Н. Нарушения кровообращения в головном и спинном мозге. Болезни нервной системы. Руководство для врачей. Под ред. Н.Н. Яхно. М.: Медицина, 2005, 1: 232-303.Скворцова В.И., Губский Л.В., Стаховская Л.В. и др. Ишемический инсульт. Неврология, национальное руководство. Под редакцией Е.И. Гусева, А.И. Коновалова, В.И. Скворцовой. М.: ГЭОТАР-МЕДИА, 2009: 592-615.Скворцова В.И., Губский Л.В., Стаховская Л.В. и др. Ишемический инсульт. Неврология, национальное руководство. Под редакцией Е.И. Гусева, А.И. Коновалова, В.И. Скворцовой. М.: ГЭОТАР-МЕДИА, 2009: 592-615.Парфенов В.А., Хасанова Д.Р Ишемический инсульт. М.: МИА, 2012, 288.Парфенов В.А., Хасанова Д.Р Ишемический инсульт. М.: МИА, 2012, 288.European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis., 2008, 25: 457-507.European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis., 2008, 25: 457-507.Van de Port I., Wood-Dauphinee S, Lindeman E, Kwakkel G. Effects of exercise training programs on walking competency after stroke: a systematic review. Am]PhysMedRehabil, 2007, 86: 935-951.Van de Port I., Wood-Dauphinee S, Lindeman E, Kwakkel G. Effects of exercise training programs on walking competency after stroke: a systematic review. Am]PhysMedRehabil, 2007, 86: 935-951.Tyson SF, Kent PM. Orthotic devices after stroke and other nonprogressive cerebral brain lesions. Cochrane Database Sys Rev 2009, CD 006187.Tyson SF, Kent PM. Orthotic devices after stroke and other nonprogressive cerebral brain lesions. Cochrane Database Sys Rev 2009, CD 006187.Cherney LR, Patterson JP, Raymer A et al. Evidence-based systematic review: effects of intensity of treatment and constraint-induced language therapy for individuals with stroke-induced aphasia. J Speech Lang Hear Res, 2008, 51: 1282-1299.Cherney LR, Patterson JP, Raymer A et al. Evidence-based systematic review: effects of intensity of treatment and constraint-induced language therapy for individuals with stroke-induced aphasia. J Speech Lang Hear Res, 2008, 51: 1282-1299.Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke. 2005, 36: 1330-1340.Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke. 2005, 36: 1330-1340.Hackett ML, Anderson CS, House AO et al. Interventions for Treating Depression After Stroke. Stroke. 2009, 40: 487-488.Hackett ML, Anderson CS, House AO et al. Interventions for Treating Depression After Stroke. Stroke. 2009, 40: 487-488.Cerebrovascular disease, cognitive impairment and dementia. Second edition of Cerebrovascular disease and dementia. Edited by O'Brien J., Ames D., Gustafson L. еt al. Martin Dunitz, 2004.Cerebrovascular disease, cognitive impairment and dementia. Second edition of Cerebrovascular disease and dementia. Edited by O'Brien J., Ames D., Gustafson L. еt al. Martin Dunitz, 2004.Furie KL., Kasner SE., Adams RJ et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011, 42: 227-276.Furie KL., Kasner SE., Adams RJ et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011, 42: 227-276.Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014. DOI: 10.1161/STR.0000000000000024.Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014. DOI: 10.1161/STR.0000000000000024.Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med]., 1995, 108: 710-717.Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med]., 1995, 108: 710-717.PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient schaemic attack Lancet, 2001, 358: 1033-1041.PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient schaemic attack Lancet, 2001, 358: 1033-1041.CAPRIE Streering Commitee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996, 348: 1329-1339.CAPRIE Streering Commitee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996, 348: 1329-1339.

The authors declare that there are no conflicts of interest present.